Effect of PSC 833, an inhibitor of P-glycoprotein, on 1,2-dimethylhydrazine-induced liver carcinogenesis in rats

Carcinogenesis

Volumn 24, Issue 12, 2003, Pages 1977-1984

  Kankesan, Janarthanan ^a   Yusuf, Aroon ^a   Laconi, Ezio ^c   Vanama, Ramesh ^a   Bradley, Grace ^a   Thiessen, Jake J ^b   Ling, Victor ^d   Rao, Prema M ^a   Rajalakshmi, Srinivasan ^a   Sarma, Dittakavi S R ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF CAGLIARI   (Italy)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIMETHYLHYDRAZINE; GLYCOPROTEIN P; OROTIC ACID; PROTEIN INHIBITOR; VALSPODAR;

ANIMAL EXPERIMENT; ANIMAL FOOD; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; EXPERIMENTAL NEOPLASM; INCIDENCE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER NODULE; NONHUMAN; PARTIAL HEPATECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SAMPLE SIZE; STATISTICAL SIGNIFICANCE; TUMOR GROWTH;

1,2-DIMETHYLHYDRAZINE; ANIMALS; BODY WEIGHT; CARCINOGENS; CYCLOSPORINS; DIMETHYLHYDRAZINES; DOSE-RESPONSE RELATIONSHIP, DRUG; LIVER; LIVER NEOPLASMS; MALE; NEOPLASMS, EXPERIMENTAL; OROTIC ACID; P-GLYCOPROTEIN; RATS; RATS, INBRED F344; TIME FACTORS;

EID: 10744231610     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/bgg159     Document Type: Article

References (48)

1. Bradley,G., Sharma,R., Rajalakshmi,S. and Ling,V. (1992) P-glycoprotein expression during tumor progression in the rat liver. Cancer Res., 52, 5154-5161.
2. Lee,C.H., Bradley,G. and Ling,V. (1994) Expression of p-glycoprotein in normal and malignant rat liver cells. Cold Spring Harbor Symposia on Quantitative Biology, LIX, 607-615.
3. Thorgeirsson,S.S., Huber,B.E., Sorrell,S., Fojo,A., Pastan,I. and Gottesman,M.M. (1987) Expression of the multidrug-resistant gene in hepatocarcinogenesis and regenerating rat liver. Science, 236, 1120-1122.
4. Fairchild,C.R., Ivy,S.P., Rushmore.T., Lee,G., Koo,P., Goldsmith,M.E., Myers,C.E., Farber,E. and Cowan,K.H. (1987) Carcinogen-induced mdr overexpression is associated with xenobiotic resistance in rat preneoplastic liver nodules and hepatocellular carcinomas. Proc. Natl Acad. Sci. USA, 84, 7701-7705.
5. Kuo,M.T., Zhao,J.Y., Teeter,L.D., Ikeguchi,M. and Chisari,F.V. (1992) Activation of multidrug resistance (P-glycoprotein) mdr3/mdr1a gene during the development of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell Growth Differ., 3, 531-540.
6. Fardel,O., Loyer,P., Lecureur,V., Glaise,D. and Guillouzo,A. (1994) Constitutive expression of functional P-glycoprotein in rat hepatoma cells. Eur. J. Biochem., 219, 521-528.
7. Teeter,L.D., Becker,F.F., Chisari,F.V., Li,D.J. and Kuo,M.T. (1990) Overexpression of the multidrug resistance gene mdr3 in spontaneous and chemically induced mouse hepatocellular carcinomas. Mol. Cell. Biol., 10, 5728-5735.
8. Burt,R.K., Garfield,S., Johnson,K. and Thorgeirsson,S.S. (1988) Transformation of rat liver epithelial cells with v-H-ras or v-raf causes expression of MDR-1, glutathione-S-transferase-P and increased resistance to cytotoxic chemicals. Carcinogenesis, 9, 2329-2332.
9. Goldstein,L.J. (1996) MDR1 gene expression in solid tumours. Eur. J. Cancer, 32A, 1039-1050.
10. Kuo,M.T., Bao,J.J., Curley,S.A., Ikeguchi,M., Johnston,D.A. and Ishikawa,T. (1996) Frequent coordinated overexpression of the MRP/GS-X pump and gamma-glutamylcysteine synthetase genes in human colorectal cancers. Cancer Res., 56, 3642-3644.
11. Salmon,S.E., Grogan,T.M., Miller,T., Scheper,R. and Dalton,W.S. (1989) Prediction of doxorubicin resistance in vitro in myeloma, lymphoma and breast cancer by P-glycoprotein staining. J. Natl Cancer Inst., 81, 696-701.
12. Schneider,J., Bak,M., Efferth,T., Kaufmann,M., Mattern,J. and Volm,M. (1989) P-glycoprotein expression in treated and untreated human breast cancer. Br. J. Cancer, 60, 815-818.
13. Gasparini,G., Bevilacqua,P., Pozza,F., Meli,S. and Weidner,N. (1993) P-glycoprotein expression predicts response to chemotherapy in previously untreated advanced breast cancer. Breast, 2, 27-32.
14. Sugawara,I., Kataoka,I., Morishita,Y., Hamada,H., Tsuruo,T., Itoyama,S. and Mori,S. (1988) Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res., 48, 1926-1929.
15. Teeter,L.D., Estes,M., Chan,J.Y., Atassi,H., Sell,S., Becker,F.F. and Kuo,M.T. (1993) Activation of distinct multidrug-resistance (P-glycoprotein) genes during rat liver regeneration and hepatocarcinogenesis. Mol. Carcinogen., 8, 67-73.
16. Itsubo,M., Ishikawa,T., Toda,G. and Tanaka,M. (1994) Immunohistochemical study of expression and cellular localization of the multidrug resistance gene product P-glycoprotein in primary liver carcinoma. Cancer, 73, 298-303.
17. Candell,J., Valle,V., Soler,M. and Rius,J. (1979) Acute intoxication with verapamil. Chest, 75, 200-201.
18. Twentyman,P.R. and Bleehen,N.M. (1991) Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin [corrected]. Eur. J. Cancer, 27, 1639-1642.
19. Boesch,D., Gaveriaux,C., Jachez,B., Pourtier-Manzanedo,A., Bollinger,P. and Loor,F. (1991) In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res., 51, 4226-4233.
20. Newman,M.J., Dixon,R. and Toyonaga,B. (2002) OC144-093, a novel P glycoprotein inhibitor for the enhancement of anti-epileptic therapy. Novartis Found. Symp., 243, 213-235.
21. Mistry,P., Stewart,A.J., Dangerfield,W., Okiji,S., Liddle,C., Bootle,D., Plumb,J.A., Templeton,D. and Charlton,P. (2001) In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res., 61, 749-758.
22. Hyafil,F., Vergely,C., Du Vignaud,P. and Grand-Perret,T. (1993) In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res., 53, 4595-4602.
23. Dantzig,A.H., Shepard,R.L., Cao,J., Law,K.L., Ehlhardt,W.J., Baughman,T.M., Bumol,T.F. and Starling,J.J. (1996) Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res., 56, 4171-4179.
24. Lehne,G. and Rugstad,H.E. (1998) Cytotoxic effect of the cyclosporin PSC 833 in multidrug-resistant leukaemia cells with increased expression of P-glycoprotein. Br. J. Cancer, 78, 593-600.
25. Cabot,M.C., Giuliano,A.E., Han,T.Y. and Liu,Y.Y. (1999) SDZ PSC 833, the cyclosporine A analogue and multidrug resistance modulator, activates ceramide synthesis and increases vinblastine sensitivity in drug-sensitive and drug-resistant cancer cells. Cancer Res., 59, 880-885.
26. Lucci,A., Han,T.Y., Liu,Y.Y., Giuliano,A.E. and Cabot,M.C. (1999) Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells. Cancer, 86, 300-311.
27. Bezombes,C., Maestre,N., Laurent,G., Levade,T., Bettaieb,A. and Jaffrezou,J.P. (1998) Restoration of TNF-alpha-induced ceramide generation and apoptosis in resistant human leukemia KG1a cells by the P-glycoprotein blocker PSC833. FASEB J., 12, 101-109.
28. Robinson,L.J., Roberts,W.K., Ling,T.T., Lamming,D., Sternberg,S.S. and Roepe,P.D. (1997) Human MDR 1 protein overexpression delays the apoptotic cascade in Chinese hamster ovary fibroblasts. Biochemistry, 36, 11169-11178.
29. Johnstone,R.W., Cretney,E. and Smyth,M.J. (1999) P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood, 93, 1075-1085.
30. Sadanand,V., Kankesan,J., Yusuf,A., Stewart,C., Rutka,J.T., Thiessen,J.J., Rao,P.M., Rajalakshmi,S. and Sarma,D.S.R. (2003) Effect of PSC 833, a potent inhibitor of P-glycoprotein on the growth of astrocytoma cells in vitro. Cancer Lett., 198, 21-27.
31. Covelli,A. (1997) [SDZ PSC 833: a novel modulator of MDR]. Tumori, 83, S21-S24.
32. Laconi,E., Denda,A., Rao,P.M., Rajalakshmi,S., Pani,P. and Sarma,D.S.R., (1993) Studies on liver tumor promotion in the rat by orotic acid: dose and minimum exposure time required for dietary orotic acid to promote hepatocarcinogenesis. Carcinogenesis, 14, 1771-1775.
33. Solt,D.B., Hay,J.B. and Farber,E. (1977) Comparison of the blood supply to diethylnitrosamine-induced hyperplastic nodules and hepatomas and to the surrounding liver. Cancer Res., 37, 1686-1691.
34. Feuer,G. (1988) Hepatic metabolism and carcinogenesis. Its role in hepatoma and adenocarcinoma. Ann. N.Y. Acad. Sci., 534, 541-551.
35. Sato,K., Satoh,K. and Hatayama,I. (1987) [Enzyme alterations during chemical hepatocarcinogenesis]. Gan To Kagaku Ryoho, 14, 1980-1988.
36. Sarma,D.S., Rao,P.M. and Rajalakshmi,S. (1986) Liver tumour promotion by chemicals: models and mechanisms. Cancer Surv., 5, 781-798.
37. Roomi,M.W., Ho,R.K., Sarma,D.S.R. and Farber,E. (1985) A common biochemical pattern in preneoplastic hepatocyte nodules generated in four different models in the rat. Cancer Res., 45, 564-571.
38. Tai,H.L. (2000) Technology evaluation: Valspodar, Novartis AG. Curr. Opin. Mol. Ther., 2, 459-467.
39. Lehne,G., Sorensen,D.R., Tjonnfjord,G.E., Beiske,C., Hagve,T.A., Rugstad,H.E. and Clausen,O.P. (2002) The cyclosporin PSC 833 increases survival and delays engraftment of human multidrug-resistant leukemia cells in xenotransplanted NOD-SCID mice. Leukemia, 16, 2388-2394.
40. Yamada,T., Mori,Y., Hayashi,R., Takada,M., Ino,Y., Naishiro,Y., Kondo,T. and Hirohashi,S. (2003) Suppression of intestinal polyposis in Mdr1-deficient ApcMin/+ mice. Cancer Res., 63, 895-901.
41. Lehne,G. (2000) P-glycoprotein as a drug target in the treatment of multidrug resistant cancer. Curr. Drug Targets, 1, 85-99.
42. Johnstone,R.W., Ruefli,A.A. and Smyth,M.J. (2000) Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem. Sci., 25, 1-6.
43. Ruefli,A.A., Tainton,K.M., Darcy,P.K., Smyth,M.J. and Johnstone,R.W. (2002) P-glycoprotein inhibits caspase-8 activation but not formation of the death inducing signal complex (disc) following Fas ligation. Cell Death Differ., 9, 1266-1272.
44. Azare,J., Pankova-Kholmyansky,I., Salnikow,K., Cohen,D. and Flescher,E. (2000) Selective susceptibility of transformed T lymphocytes to induction of apoptosis by PSC 833, an inhibitor of P-glycoprotein. Oncol. Res., 12, 315-323.
45. Oza,A.M. (2002) Clinical development of P glycoprotein modulators in oncology. Novartis Found. Symp., 243, 103-115, 180-185.
46. Sikic,B.I., Fisher,G.A., Lum,B.L., Halsey,J., Beketic-Oreskovic,L. and Chen,G. (1997) Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother. Pharmacol., 40 (suppl), S13-S19.
47. Bates,S.F., Chen,C., Robey,R., Kang,M., Figg,W.D. and Fojo,T. (2002) Reversal of multidrug resistance: lessons from clinical oncology. Novartis Found. Symp., 243, 83-102, 180-185.
48. Dantzig,A.H., Law,K.L., Cao,J. and Starling,J.J. (2001) Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic. Curr. Med. Chem., 8, 39-50.